Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

TRANSLATIONAL DATA PRESENTED AT ADA DEMONSTRATE ICOVAMENIB'S POTENTIAL TO PROMOTE MUSCLE PRESERVATION AND FAT REDUCTION, SUPPORTING ITS BROADER THERAPEUTIC UTILITY IN OBESITY AND DIABETES, INCLUDING AS A COMPLEMENTARY THERAPY ALONGSIDE GLP-1 RECEPTOR AGONISTS TO ENHANCE METABOLIC HEALTH OUTCOMES  CLINICAL DATA PRESENTED AT ADA FROM COVALENT-112 SHOW IMPROVEMENTS IN HBA1C AND C-PEPTIDE IN TYPE 1 DIABETES PATIENTS TREATED WITH ICOVAMENIB, WITH NO EVIDENCE OF IMMUNE ACTIVATION, AND INFLAMMATORY MARKERS STABLE OR REDUCED  ADDITIONALLY, THE COMPANY EXPANDED ITS PHASE I BMF-650 STUDY TO EVALUATE A RAPID ONE-STEP TITRATION AND ENHANCED WEIGHT LOSS POTENTIAL WITH ITS ORAL GLP-1 RECEPTOR AGONIST

BIOMEA FUSION PRESENTS NEW CLINICAL AND TRANSLATIONAL DATA FOR ICOVAMENIB AT THE AMERICAN DIABETES ASSOCIATION (ADA) 86TH SCIENTIFIC SESSIONS AND ANNOUNCES EXPANSION OF ONGOING PHASE I BMF-650 STUDY

COLLABORATION WILL ASSESS THE POTENTIAL IMPACT OF THE COMBINATION OF ICOVAMENIB AND SEMAGLUTIDE ON PHYSICAL FUNCTION, BODY WEIGHT, BODY COMPOSITION, MUSCLE HEALTH AND METABOLIC OUTCOMES LATE-BREAKING PRECLINICAL FINDINGS AT THE AMERICAN DIABETES ASSOCIATION ANNUAL MEETING JUNE 5-8 HIGHLIGHTING POTENTIAL MECHANISMS THROUGH WHICH ICOVAMENIB MAY SUPPORT METABOLIC HEALTH SAN CARLOS, CALIF., JUNE 03, 2026 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA, BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED A COLLABORATION WITH THE UNIVERSITY OF LEICESTER AS PART OF THE ONGOING PLATFORM RESEARCH STUDY TITLED INVESTIGATING AND OPTIMIZING PHYSICAL FUNCTION WITH WEIGHT LOSS: A MULTI-ARM OPEN LABEL ADAPTIVE PLATFORM TRIAL (OPAL) WHICH IS BEING LED BY PROFESSORS MELANIE DAVIES AND THOMAS YATES AT THE UNIVERSITY OF LEICESTER AND LEICESTER DIABETES CENTRE (LDC).

BIOMEA FUSION ANNOUNCES RESEARCH COLLABORATION WITH UNIVERSITY OF LEICESTER TO EVALUATE ICOVAMENIB IN COMBINATION WITH SEMAGLUTIDE IN OBESITY

SAN CARLOS, CALIF., MAY 12, 2026 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: H.C.

BIOMEA FUSION TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

SAN CARLOS, CALIF., MAY 11, 2026 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE.

BIOMEA FUSION REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SAN CARLOS, CALIF., MAY 05, 2026 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THAT THREE ICOVAMENIB ABSTRACTS HAVE BEEN SELECTED FOR LATE-BREAKING POSTER PRESENTATIONS AT THE AMERICAN DIABETES ASSOCIATION (ADA) 86TH SCIENTIFIC SESSIONS, TAKING PLACE JUNE 58, 2026 IN NEW ORLEANS. THE PRESENTATIONS INCLUDE DATA FROM ICOVAMENIB, THE COMPANY'S INVESTIGATIONAL ORAL MENIN INHIBITOR, ACROSS BOTH TYPE 1 AND TYPE 2 DIABETES, HIGHLIGHTING ITS POTENTIAL TO IMPROVE BETA CELL FUNCTION AND SUPPORT METABOLIC HEALTH.

BIOMEA FUSION ANNOUNCES POSTER PRESENTATIONS OF ICOVAMENIB AT THE AMERICAN DIABETES ASSOCIATION (ADA) 86TH SCIENTIFIC SESSIONS

SAN CARLOS, CALIF., APRIL 27, 2026 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED POSITIVE 52-WEEK RESULTS FROM ITS PHASE 2 COVALENT-112 TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF ICOVAMENIB IN PATIENTS WITH TYPE 1 DIABETES (T1D). THESE DATA ARE BASED ON A PROOF-OF-CONCEPT STUDY ENROLLING SMALL SUBSETS OF STAGE 3 T1D PATIENTS DOSED WITH ICOVAMENIB AT 100 MG AND 200 MG IN TWO COHORTS (PATIENTS DIAGNOSED WITHIN 3 YEARS AND THOSE DIAGNOSED WITHIN 3-15 YEARS).

BIOMEA FUSION ANNOUNCES POSITIVE 52-WEEK RESULTS FROM PHASE 2 COVALENT-112 TRIAL IN TYPE 1 DIABETES SHOWING C-PEPTIDE IMPROVEMENT AND DURABILITY FOLLOWING 12-WEEKS OF ICOVAMENIB TREATMENT

COVALENT-211 PHASE II ENROLLING INSULIN-DEFICIENT TYPE 2 DIABETES PATIENTS COVALENT-212 PHASE II ENROLLING TYPE 2 DIABETES PATIENTS UNCONTROLLED WITH A GLP-1 RECEPTOR AGONIST-BASED THERAPY TOPLINE 26-WEEK PRIMARY ENDPOINT DATA FROM BOTH PHASE II STUDIES ANTICIPATED 4Q 2026

BIOMEA FUSION ANNOUNCES FIRST PATIENT DOSED IN NEWLY INITIATED PHASE II PROGRAMS ENROLLING TYPE 2 DIABETES PATIENTS FAILING ON STANDARD-OF-CARE THERAPIES

SAN CARLOS, CALIF., MARCH 24, 2026 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR BIOMEA FUSION OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A BUSINESS UPDATE.

BIOMEA FUSION REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SAN CARLOS, CALIF., MARCH 14, 2026 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA, BIOMEA FUSION, OR THE COMPANY) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THAT JUAN PABLO FRAS, MD, DELIVERED AN ORAL PRESENTATION AT THE 19TH INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES & TREATMENTS FOR DIABETES (ATTD) IN BARCELONA ON MARCH 14, 2026 HIGHLIGHTING POSITIVE 52-WEEK FOLLOW-UP RESULTS FROM THE COMPANY'S PHASE II COVALENT-111 STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF ICOVAMENIB IN PATIENTS WITH TYPE 2 DIABETES (T2D).

BIOMEA FUSION PRESENTS PHASE II COVALENT-111 DATA IN TYPE 2 DIABETES AT THE 19TH INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES & TREATMENTS FOR DIABETES 2026

SAN CARLOS, CALIF., FEB. 19, 2026 (GLOBE NEWSWIRE) -- BIOMEA FUSION, INC. (BIOMEA OR COMPANY OR COMPANY MANAGEMENT) (NASDAQ: BMEA), A CLINICAL-STAGE DIABETES AND OBESITY COMPANY, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: OPPENHEIMER 36TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE: BIOMEA WILL PRESENT VIRTUALLY ON FEBRUARY 26, 2026, AT 10:00 AM (EDT).

Biomea Fusion, Inc.

BMEA

Price

Financial Reports

No items found.

Press Releases

Biomea Fusion, Inc.

BMEA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BMEA